E-therapeutics Share Discussion Threads

[dynoport] 16/10/2013 10:20

market does not like the results, down 22% as I write. probably because of dropping one of the trials

[ceohunter] 27/6/2013 15:15

To view e-Therapeutics' presentation from Proactive Investors One2One Forum, click on the following link:-

[ceohunter] 17/6/2013 08:25

The directors of e-Therapeutics plc (AIM: ETX), ValiRx (AIM: VAL) and Deltex Medical Group (AIM: DEMG) will be presenting:Wednesday the 26th June 2013.

Venue: The Midland Hotel, Peter Street, Manchester.

The presentations will start at 6:00pm and finish at approx 8:00pm. After the presentations are complete the directors will also be available to take questions during a free canapé and wine reception.

REGISTER HERE: [...]

[leedsu36] 18/5/2013 10:49

Impressive to hold such gains,speaks volumes.

[ceohunter] 17/5/2013 10:57

To view Motive Television's presentation from last night's Proactive Investors One2One Investor Forum, click on the following link:

[beaufort1] 16/5/2013 10:51

Still nudging up, despite the glacial progress. It seems that ETX is beginning to get a bit of visibility in the market.
B1

[leedsu36] 15/5/2013 16:03

I've been called a few things in my time,but those two are a welcome change.

All in the public domain B1 and i was at the back of the class when professorships were being brandished around,anyway gl here,Friday should bring some joy after the presentation on Thursday.

[beaufort1] 15/5/2013 15:05

Leeds you're a scholar and a gentleman - where did you get all this stuff (or are you really Prof Malcolm Young???!
B1

[lucky_punter] 15/5/2013 14:08

UPDATE - e-Therapeutics surges on phase I progress for lead candidate

e-Therapeutics (LON:ETX) has been encouraged by the first findings of the phase I trial of its lead drug, ETS2101.
The company stands ready to whisk the cancer drug into efficacy trials if phase I trials over the coming year go well.

[leedsu36] 15/5/2013 14:04

Oh nearly forgot,there's a presentation tomorrow and you usually get a flurry of activity if they present well and generate lots of interest,what with only 15% to deal with,potential for handsome gains.

[leedsu36] 15/5/2013 14:00

It is mainly seeking novel treatments for cancer and disorders of the nervous system.
It hopes to license ETS2101 in 2017 and has earmarked £25m for completion of trials to that point. "If these trials are positive, we would expect to have a significant deal that would be transformative," said Prof Young.

E-Therapeutics also announced that it has applied for further trials of ETS6103, which aims to treat major depressive disorders.
It hopes that the drug will provide its first licensing deal, in 2015.

It is also nearing completion of pre-clinical work on a drug to treat C. difficile infection and will carry out other drug discovery and development.

Prof Young described the timescales in the sector as "glacial." But he added: "When you get there it's magical."

The biggest investors are Invesco, with 49.8 per cent, Aviva with 16.2 per cent and Prof Young with 7.8 per cent. The shares closed up 12.5 per cent to 33.75p.

There you go B1 that should bring all current and potential investors up to speed with company position,quite an healthy position i'd say and with the sort of clout Invesco and Aviva have no worries for future.

[leedsu36] 15/5/2013 13:54

This approach offers the longer term prospect of revenues,

in the form of upfront payments,

progress-based milestone payments and royalties,

but also the shorter-term certainty of research expenditure without immediate earnings.

Earlier this year, the company raised £40m gross through a placing.
Its latest results, announced on Tuesday, show a net loss of £4.2m for the year to January 31, against a £3.2m loss last time, and its highest annual loss.

"Increased losses simply reflect increased R&D expenditure," said Daniel Elger, chief financial officer.

Year-end cash and liquid resources of £9.8m, coupled with the placing, mean that e-Therapeutics has around £48m available to support its discovery and development plans through to 2017.

[leedsu36] 15/5/2013 13:51

In a result described as "encouraging" by Malcolm Young, chief executive, one UK patient experienced a "partial response", a standard assessment method meaning the shrinking of a tumour by at least 30 per cent.
"It's a surprise to see we already have evidence that it's pharmacologically active," said Prof Young. While cautioning that the trial is still at an early stage, he added: "It slightly derisks where we are."
The company, a Newcastle University spinout, which floated on Aim in November 2007 at 67p a share, uses network pharmacology, a new approach to the discovery of medicines. It aims to discover promising drug candidates, then take them through clinical trials to a point where they can be licensed to pharmaceutical companies for late-stage development and commercialisation.

[leedsu36] 15/5/2013 13:49

High quality global journalism requires investment. Please share this article with others using the link below, do not cut & paste the article. See our Ts&Cs and Copyright Policy for more detail. Email [e-mail] to buy additional rights.

A patient suffering from advanced oesophageal cancer has responded positively during an early drug trial, e-Therapeutics , the Aim-listed drug discovery and development company, said on Tuesday.
Cancer drug ETS2101, its most commercially significant potential product, is being trialled in California and at hospitals in Newcastle and Leeds in the UK, with patients being given gradually increasing doses.

[leedsu36] 15/5/2013 12:01

Here try this....

DRUG discovery and development company e-Therapeutics recorded a steep rise in its share price after announcing positive progress in several drugs trials in its preliminary results.

The AIM-listed company, based in Newcastle, reported growing momentum in key areas of the business, prompting shares to rise 12.5% to close at 33.75p, despite noting full-year net losses of £4.2m, up from £3.2m.

The company's year-end cash and liquid resources of £9.8m at January 31, 2013, have now been boosted to £48m after its March shares placing, money which will allow it to increase investment in research and development.

Together with expected receipts from R&D tax credits and interest, the resources are intended to support all of the company's currently planned discovery and development activities into 2017.

At that point, the directors hope to have made an out-licensing deal for its most important drug, the cancer drug known as ETS2101, which will have £25m pumped into its development.

The Newcastle University spin-out company started clinical trials in the UK – including the Sir Bobby Robson Cancer Trials Research Centre in Newcastle – and US for the cancer drug.

Both trials have a dose-escalating design, in which groups of patients receive increasing doses in a bid to discover the best way to administer it, and having received relatively low dose levels no serious adverse reactions were recorded.

In the lab, the drug was found to be able to kill off all types of cancer, yet it is not known how well it will work in human trials so it is now being tested on people with all forms of solid tumours.

Chief executive Prof Malcolm Young said e-Therapeutics was the fourth highest riser on AIM after issuing its results – evidence that investors are taking an interest in the company's progress.

He added: "We've got a large amount of money – around £50m to £60m – to deploy between now and 2017, so we are definitely sitting pretty financially.

"And in terms of progress of assets, we know that the lead cancer drug is pharmacologically active in man, and with the anti-depressant drug the discovery team is moving on further." The firm currently employs 17 people, with more becoming involved during trials, and there is scope for more job creation.

Prof Young said: "We will potentially take more people on, but it won't be a step change.

"I often ask myself the £50bn question – what would I do if we had £50bn in the bank instead of £50m, and would we be doing things differently, and the answer is not radically, no."

[leedsu36] 15/5/2013 11:50

Seeing as you like it that much,

e-Therapeutics continues development
e-Therapeutics' (ETX) results held some surprises after the company's detailed update at the time of its fundraising in March,

except for the probability that data for its early stage trials for cancer drug ETS2101 will be available ahead of schedule at the end of this year.

Analysts were excited by some initial data readouts that showed a partial improvement for one patient with an untreatable tumour in a 12-patient dosing study.

ETS2101 is e-Therapeutics' main product and is being investigated to determine its effectiveness in a number of hard to treat cancers.

[beaufort1] 15/5/2013 09:29

Thanks Leeds!

[leedsu36] 14/5/2013 19:58

You might like this then B1,

Commenting on the results, Professor Malcolm Young, chief executive officer of e-Therapeutics, said:

"We have growing momentum in the key areas of our business. Use of our innovative network pharmacology platform to discover new drugs is on track while our most significant product candidate, the cancer drug ETS2101, is making good progress in the clinic."

The share price advanced 15% to 34.4 pence, valuing the Newcastle-based group at £48mln.

However City broker Panmure Gordon believes the stock has further to go as tweaked its target 3 pence higher to 70 pence a share.

Analyst Savvas Neophytou said: "We had been anticipating safety data from the company's lead product candidate ETS2101 in the fourth quarter.

"Therefore it was a positive surprise to hear today's announcement of strong success in the treatment of one particular patient whose tumour was greatly reduced in size.

"This sector is not used to success so the pessimists will scream sample size, chance event and other such instruments of caution.

"They would be right from a purist point of view but the fact remains one particular patient who had ran out of all therapeutic options is still alive as a result of ETS2101 and that is a significant achievement for the company's first shot at goal."

[beaufort1] 14/5/2013 17:18

Just amazed there has been so little reaction to results and share price jump

[ceohunter] 14/5/2013 09:59

The directors of Alliance Pharma (AIM: APH), Motive Television Plc (AIM: MTV), Brightside Group (AIM: BRT) and e-Therapeutics plc (AIM: ETX) will be presenting:
Thursday the 16th May 2013,
Chesterfield Mayfair Hotel, 35 Charles Street, Mayfair, W1J 5EB

REGISTER HERE:

[beaufort1] 14/5/2013 08:45

Very positive response to the results.

[dibs61] 13/5/2013 15:05

We can never accurately forecast when news is going to arrive can we? At least, if we can, I've not seen it done yet, unless by good fortune.

[beaufort1] 13/5/2013 14:58

Hooray, well done Dibs! Good timing I think, but I dont' know what the rise is based on. Results tomorrow, but no immediate news expected on trials. Let's see what tomorrow holds.
B1